ArticleFrontiers in immunology2026
Risk factors and immune landscape of early local tumor progression after microwave ablation for lung cancer: a retrospective nested case-control study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives: Microwave ablation (MWA) is an effective therapy for early-stage inoperable non-small cell lung cancer (NSCLC), yet its efficacy is limited by early local tumor progression (LTP). As early LTP is often suggestive of incomplete ablation, this study aimed to identify its risk factors and to characterize the associated changes in systemic immune parameters. Methods: This single-center retrospective nested case-control study enrolled patients with NSCLC who underwent MWA between January 1, 2021, and December 31, 2023. Patients were divided into an early LTP group (LTP ≤6 months post-MWA) and a control group. Clinical data and peripheral blood immune parameters at pre-MWA, one-week post-MWA, and one-month post-MWA were collected. Univariate and multivariate logistic regression analyses were used to identify independent risk factors and dynamic changes in immune indicators compared between groups. Results: A total of 76 patients were included (19, early LTP group; 57, control group). Multivariate analysis identified three independent risk factors for early LTP: maximum tumor diameter >30 mm (OR = 2.681, 95%CI: 1.218-5.901, P = 0.014), distance to hilum ≤10 mm (OR = 3.280, 95%CI: 1.678-6.411, P = 0.001), and ablative safety margin (≤5.0 mm) (OR = 4.152, 95%CI: 1.922-8.968, P < 0.001). Comparative analysis of peripheral blood immune parameters revealed distinct patterns between groups at one-month post-MWA. Compared to the control group, the early LTP group exhibited a significant reduction in CD4 Conclusion: Large tumor size, proximity to the pulmonary hilum, and an insufficient ablative safety margin are key risk factors for early LTP post-MWA. The development of early LTP is associated with significant alterations in specific peripheral blood immune cell subsets and cytokine levels at one-month post-MWA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.